FDA calls for investigation into industry influence during Alzheimer’s drug approval Post date 12 July 2021 ← Sixty seconds on . . . the George Cross → Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM)